A syringe glide force test measures the steady-state axial force required to depress the plunger of a syringe, performed on a texture analyzer per ISO 7886-1:2017 for sterile hypodermic syringes and ISO 11040-4 for glass prefilled syringes. The test reports two distinct force values — break-loose force (F1), the peak force to initiate plunger movement from rest (typically 4–20 N), and glide force (F2), the steady-state force during continuous depression (typically 3–15 N). Both values directly impact patient dosing accuracy and auto-injector reliability, which is why every sterile-syringe release spec and every combination drug-device filing includes F1/F2 acceptance criteria. The KHT TA-30 Pharmaceutical Texture Analyzer performs this test with a dedicated syringe activation rig, 500 N load cell, 100 mm/s compression speed per ISO 7886-1, and 21 CFR Part 11–compliant data capture as standard.
Syringe Force Testing Requirements for Prefilled Syringes and Auto-Injectors
Three syringe subtypes drive most pharmaceutical force testing:
Standard sterile hypodermic syringes (Luer-lok, Luer-slip, disposable). Regulated by ISO 7886-1:2017. The test verifies that the plunger moves under reasonable human thumb force — if F1 exceeds 20 N, the user cannot reliably initiate injection. Typical commercial spec: F1 ≤ 15 N, F2 ≤ 10 N.
Glass prefilled syringes (PFS) used for biologics, vaccines, and parenteral small molecules. Regulated by ISO 11040-4:2015. The added complication is that the PFS sits at 2–8 °C for months to years before use, during which silicone oil on the barrel wall can migrate, pool, and dry, raising F1 significantly. Stability-indicating F1/F2 data is therefore required across the product shelf life.
Auto-injectors and pen injectors (spring-driven, gas-propelled, or electromechanical). Regulated by ISO 11608-1:2022. The test measures trigger activation force (what the user feels on the button), total force delivered to the drug cartridge, and injection duration. Typical activation force: 15–50 N.
All three subtypes use the same core instrument — a texture analyzer with a low-compliance frame, 500 N load cell, 100 mm/s capable crosshead, and 0.001 mm displacement resolution. The KHT TA-30 meets every one of those specs and includes the syringe activation rig as a standard accessory.
The force-testing requirement is not optional for any of these products. FDA's 21 CFR 211.165 requires release testing of every finished drug product batch, and sterile-syringe monographs in USP, EP, and JP all reference ISO 7886-1 or its regional equivalents for plunger force.
Break-Loose Force vs. Glide Force: Key Distinctions
The two metrics measure different failure modes.
Break-loose force (F1) is the peak force recorded at the very start of plunger travel — typically within the first 0.5–2 mm of compression. Physically, F1 overcomes static friction between the rubber stopper and the glass or polymer barrel. Elevated F1 almost always indicates a siliconisation problem: either too little silicone oil (insufficient lubrication) or silicone oil that has dried, migrated, or cross-linked during storage.
Glide force (F2) is the steady-state force sustained after break-loose, over the bulk of plunger travel (typically between 10 % and 90 % of full stroke). Physically, F2 is kinetic friction plus fluid viscous drag through the needle. Elevated F2 typically indicates either a barrel dimensional issue (out-of-tolerance diameter) or insufficient bulk siliconisation.
A useful diagnostic heuristic:
| Observation | Likely Root Cause |
|---|---|
| F1 high, F2 normal | Dried / migrated silicone at stopper contact zone |
| F1 normal, F2 high | Insufficient bulk silicone or barrel out-of-tolerance |
| Both high | Under-siliconised batch; reject |
| Both acceptable, F2 rising over shelf life | Silicone migration toward needle end — stability flag |
This failure-mode distinction is why ISO 7886-1 requires reporting both values rather than a single peak or average — each one points to a different manufacturing control.
For the other two combination drug-device applications on the same platform, see the injectable and transdermal texture analysis hub.
ISO 7886 and ISO 11040-4 Test Method Requirements
ISO 7886-1:2017 — Sterile hypodermic syringes for single use. Key requirements:
- Test speed: 100 mm/min (1.67 mm/s) — specified in Annex G
- Sample conditioning: 23 °C ± 2 °C for ≥ 3 hours before test
- Minimum sample size: 3 syringes per batch per release test
- Measurement: Peak force during first 5 mm (F1) and mean force across middle 80 % of stroke (F2)
- Syringe mounted in rigid fixture; plunger compressed by instrument crosshead
ISO 11040-4:2015 — Glass prefilled syringes, functional performance. Adds:
- Test speed 100 mm/min or 190 mm/min (both accepted depending on device class)
- Stability testing required at 5 °C ± 3 °C, 25 °C ± 2 °C / 60 % RH, 40 °C ± 2 °C / 75 % RH per ICH Q1A
- F1 and F2 reported at each stability timepoint
- Additional attribute: dead-volume displacement
ISO 11608-1:2022 — Needle-based injection systems. Covers auto-injectors:
- Activation force measured at the user-facing button (trigger)
- Cartridge force measured independently via instrumented cartridge
- Test speed dependent on device mechanism (spring vs electromechanical)
- Duration of injection captured as time-to-complete-stroke
The KHT TA-30's crosshead handles test speeds from 0.001 to 40 mm/s, covering all three standards without accessory changes. Syringe mounting fixtures are interchangeable and snap into the universal probe interface.
KHT TA-30 Syringe Rig Setup and Measurement Protocol
Setup is straightforward once the daily calibration is complete.
Required hardware:
- KHT TA-30 Pharmaceutical Texture Analyzer with 500 N load cell
- Syringe activation rig (adjustable barrel clamp, compatible with 1 mL, 3 mL, 5 mL, 10 mL and 20 mL sizes)
- Plunger compression tip (flat, zero-deflection, 10 mm diameter)
- Temperature-controlled chamber for stability protocols (optional)
Recommended test parameters (per ISO 7886-1):
- Test speed: 100 mm/min (1.67 mm/s)
- Trigger force: 0.05 N (contact detection)
- Total travel: full plunger stroke minus 2 mm safety margin
- Data acquisition rate: 500 Hz
- F1 window: first 5 mm of stroke (peak force)
- F2 window: 10 %–90 % of remaining stroke (mean force)
Step-by-Step Protocol (HowTo):
- Calibrate. Daily force-and-displacement calibration with class E1 weights. Log to audit trail.
- Install 500 N load cell. Verify via universal probe interface; software auto-recognises cell.
- Mount syringe activation rig. Confirm barrel clamp size matches syringe (1/3/5/10/20 mL).
- Load syringe. Needle end down, plunger up; tighten clamp until syringe is rigid but not stressed.
- Condition sample. 23 °C ± 2 °C for ≥ 3 hours. Record conditioning start time in audit log.
- Prime if required. Some PFS protocols prime to remove dead volume; most do not.
- Set test parameters. Speed 1.67 mm/s; trigger 0.05 N; full stroke; 500 Hz data rate.
- Run test. Instrument auto-zeros at contact; records force-distance curve to database.
- Analyse. Software auto-detects F1 (peak, first 5 mm) and F2 (mean, 10–90 % stroke).
- Report. PDF with audit trail; CSV for archive; electronic signature from operator and reviewer.
The universal probe interface means rigs from Stable Micro Systems, Cell Instruments, and custom fabricators mount directly. Labs migrating from enterprise-brand instruments can retain existing syringe fixtures.
Acceptance Criteria and Regulatory Documentation
Typical commercial acceptance criteria, derived from ISO 7886-1 guidance and published literature:
| Syringe Type | F1 (Break-Loose) Typical Spec | F2 (Glide) Typical Spec |
|---|---|---|
| 1 mL insulin syringe | ≤ 10 N | ≤ 6 N |
| 3 mL standard disposable | ≤ 15 N | ≤ 10 N |
| 5–10 mL standard | ≤ 20 N | ≤ 15 N |
| 1 mL prefilled (biologic) | ≤ 20 N | ≤ 15 N |
| 1 mL prefilled (vaccine, aq) | ≤ 10 N | ≤ 6 N |
| Auto-injector activation | Per device spec (15–50 N) | n/a |
Stability-indicating F1/F2 data is submitted in the CMC section of an IND or NDA and in post-approval batch release records. The KHT TA-30 writes every test to a 21 CFR Part 11–compliant audit trail, captures electronic signatures, and exports a validated PDF report — every one of which is required for FDA, EMA, and PMDA submissions.
The IQ/OQ/PQ validation package ships with the instrument and is revised annually at no additional charge. Calibration intervals are 12 months, with on-site calibration service available or self-calibration using traceable weights.
Standards Compliance Matrix
| Standard | Scope | KHT TA-30 Coverage |
|---|---|---|
| ISO 7886-1:2017 | Sterile hypodermic syringes — plunger force test | ✓ Meets — 100 mm/min speed, F1/F2 auto-detection |
| ISO 11040-4:2015 | Glass prefilled syringes — functional performance | ✓ Meets — stability-compatible, dedicated rig |
| ISO 11608-1:2022 | Needle-based injection systems (auto-injectors) | ✓ Meets — trigger-force detection, duration logging |
| ISO 7864 | Sterile hypodermic needles | ✓ Meets with needle-penetration fixture |
| 21 CFR Part 11 | Electronic records and signatures | ✓ Standard — audit trail + e-sig built in |
| EMA Annex 11 | EU equivalent of Part 11 | ✓ Standard |
| USP <1> | Injections — general chapter | ✓ Supports QC workflows |
Key Measurement Parameters
| Parameter | Typical Range | Acceptance Criterion (example) | Notes |
|---|---|---|---|
| Break-loose force (F1) | 4–20 N | ≤ 15 N | Peak force, first 5 mm |
| Glide force (F2) | 3–15 N | ≤ 10 N | Mean force, 10–90 % stroke |
| Dead-volume residual | 0.01–0.1 mL | Per device spec | Post-full-stroke drug retention |
| Auto-injector activation | 15–50 N | Per device spec | Trigger-button force |
| Injection duration | 1–15 s | Per device spec | Auto-injector time-to-empty |